Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT L576P||melanoma||sensitive||SEL201||Preclinical - Cell line xenograft||Actionable||In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cells harboring KIT L576P in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).||29035277|
|KIT L576P||melanoma||sensitive||KIT Inhibitor||Dasatinib||Case Reports/Case Series||Actionable||In a clinical study, two patients with melanoma harboring KIT L576P, one who had progressed on Gleevec (imatinib), demonstrated initial clinical benefit following treatment with Sprycel (dasatinib); however, one patient progressed after 3 months, and the other patient progressed after 4 months of treatment (PMID: 19671763).||19671763|
|KIT L576P||melanoma||sensitive||KIT Inhibitor||Dasatinib||Preclinical - Cell culture||Actionable||In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT L576P in culture (PMID: 29035277).||29035277|
|KIT L576P||Advanced Solid Tumor||sensitive||KIT Inhibitor||Axitinib||Preclinical - Cell culture||Actionable||In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT L576P in culture (PMID: 31205508).||31205508|
|KIT L576P||melanoma||unknown||KIT Inhibitor||Imatinib||Case Reports/Case Series||Actionable||In a clinical case study, Gleevec (imatinib) treatment resulted in initial tumor reduction, but was followed by disease progression at all tumor sites in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153).||20372153|
|KIT L576P||melanoma||predicted - sensitive||KIT Inhibitor||Nilotinib||Case Reports/Case Series||Actionable||In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including three melanoma patients harboring KIT L576P demonstrating a partial response (PMID: 28327988).||28327988|
|KIT L576P||melanoma||predicted - sensitive||KIT Inhibitor||Bevacizumab + Sorafenib||Case Reports/Case Series||Actionable||In a Phase I trial, a melanoma patient harboring KIT L576P demonstrated sensitivity to the combination treatment of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in a partial response for 8 months (PMID: 25363205).||25363205|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|